



## A Venture to Discover the Treatment of Coronavirus Disease 2019 (COVID 19): SARS-CoV-2

Soumitra Sahana<sup>1\*</sup>, Sourav Nag<sup>1</sup>, Prasit Roy<sup>1</sup>, Reshmi Paul<sup>1</sup>, Sk Abdur Rahamat<sup>1</sup>, Indranil Chatterjee<sup>2</sup>, Suman Kumar Nath<sup>3</sup> and Snehansu Biswas<sup>3</sup>

<sup>1</sup>B. Pharm, Birbhum Pharmacy School, Birbhum, West Bengal, India

<sup>2</sup>Assistant Professor, Department of Microbiology, Birbhum Pharmacy School, Birbhum, West Bengal, India

<sup>3</sup>Assistant Professor, Department of Pharmacognosy, Birbhum Pharmacy School, Birbhum, West Bengal India

\*Corresponding Author: Soumitra Sahana, B. Pharm, Birbhum Pharmacy School, Birbhum, West Bengal, India.

Received: August 18, 2020

Published: September 16, 2020

© All rights are reserved by Soumitra Sahana, et al

### Abstract

In December 31, 2019, hospitals pronounced a cluster of instances with pneumonia of unknown motive in Wuhan, Hubei, China, attracting brilliant interest nationally and worldwide. The pandemic of coronavirus disease 2019 precipitated by means of the SARS-CoV-2 offers an unheard of venture to discover superb capsules for treatment. Given the speedy tempo of scientific discovery and medical statistics generated by means of the massive quantity of human beings unexpectedly contaminated by using SARS-CoV-2, clinicians want correct proof involving nice clinical remedies for this infection. This paper analysis the literature on all on hand records about the Treatments of COVID-19. Treatments, together with Antibodies, Vaccines, antiviral agents, convalescent plasma transfusion, corticosteroids, chloroquine and hydroxychloroquine, are mentioned in this article.

**Keywords:** Coronavirus Disease 2019; SARS-CoV-2; Vaccines; Treatment; Antibodies; Antiviral Agents; Corticosteroids; Chloroquine and Hydroxychloroquine

### Introduction

In Wuhan, China, a novel and alarmingly contagious principal peculiar (viral) pneumonia broke out in December 2019. It has due to the fact been recognized as a zoonotic coronavirus, comparable to SARS coronavirus and MERS coronavirus, and named 2019-nCoV. As of 8<sup>th</sup> February, 2020, 33,738 tested instances and 811 deaths have been stated in China [1]. Italy is presently experiencing an epidemic of COVID-19 which emerged in the Lombardy region. During the interval between Feb 25-29, 2020, we recognized forty six instances of COVID-19 pronounced in 21 international locations in Europe, Africa, North America, and South America that had been both in persons with latest journey from Italy, or who had presumed contamination by way of a traveller from Italy [2]. The modern outbreak of COVID-19 coronavirus

contamination amongst people in Wuhan [China] and its spreading round the globe is closely impacting on the world fitness and intellectual health. Despite all assets employed to counteract the spreading of the virus, extra international techniques are wanted to take care of the associated intellectual fitness troubles [3]. SARS-CoV-2 is the seventh pronounced human-infecting member of the household Coronaviridae, which additionally consists of SARS-CoV and the Middle East respiratory syndrome [MERS]-CoV. It has been recognized as the causative agent of COVID-19. Both the scientific and the epidemiological points of COVID-19 sufferers exhibit that SARS-CoV-2 contamination can lead to intensive care unit [ICU] admission and excessive mortality. About 16%-21% of humans with the virus in China have grow to be severely ill, with a 2%-3% mortality fee [4,5]. COVID-19 hastily unfold all through the country,

and the wide variety of contaminated humans steadily increased. The unfold of COVID-19 amongst humans has been proven to happen via more than one channels, such as droplets, aerosols, feces, and mouth mucus membranes [6]. The disorder is transmitted by means of inhalation or contact with contaminated droplets and the incubation duration degrees from 2 to 14 days. The signs and symptoms are typically fever, cough, sore throat, breathlessness, fatigue, malaise amongst others. The ailment is moderate in most people; in some (usually the aged and these with comorbidities), it might also development to pneumonia, acute respiratory misery syndrome (ARDS) and multi organ dysfunction. Many human beings are asymptomatic [7]. Smoking is additionally hazardous to the immune device and its responsiveness to infections, making people who smoke extra prone to infectious diseases. Previous research have proven that people who smoke are twice extra probable than non-smokers to contract influenza and have greater extreme symptoms, whilst people who smoke have been additionally referred to have greater mortality in the preceding MERS-CoV outbreak [8]. Chloroquine has been used international for greater than 70 years, and it is phase of the World Health Organization (WHO) mannequin listing of imperative medicines. It is additionally affordable and has an set up medical protection profile [9]. As of April 5, 2020, there have been greater than 1.2 million suggested instances and 69 000 deaths in extra than 200 countries. This novel Betacoronavirus is comparable to extreme acute respiratory syndrome coronavirus and Middle East respiratory syndrome coronavirus; primarily based on its genetic proximity, it probably originated from bat-derived coronaviruses with unfold with the aid of an unknown intermediate mammal host to humans [10].

## Treatments

### Antibodies

CR3022 may also be a practicable therapeutic candidate, by myself or in mixture with different neutralizing antibodies, for the prevention and remedy of COVID-19 infections. Antibodies MAb114 and REGN-EB3 have been designed for remedy of Ebola virus contamination and extensively limit mortality from Ebola virus disease [11]. Monoclonal antibodies can solely apprehend a single antigen epitope, which limits the use of MAb114 and REGN-EB3 in the cure of COVID-19. Although, the enchancement of COVID-19-specific antibodies requires a prolonged time. It is now not effortless to follow monoclonal antibodies for new pathogens to scientific exercise in a quick time [12]. The improvement of vaccines and therapeutic antibodies towards COVID-19 has vital im-

plications. Considering the surprisingly excessive identification of the receptor-binding area [RBD] in SARS-CoV-2 and SARS-CoV, the cross-reactivity of anti-SARS-CoV antibodies accompanied by COVID-19 spike protein used to be assessed [13]. Monoclonal antibodies symbolize the principal category of biotherapeutics for passive immunotherapy to combat in opposition to viral infection. The therapeutic practicable of monoclonal antibodies has been properly identified in the therapy of many diseases. Here, we summarize the viable monoclonal antibody based totally therapeutic intervention for COVID-19 with the aid of thinking about the present. Monoclonal antibodies are versatile class of prescription drugs that have been effectively used by pharmaceutical enterprise which can supply an environment friendly therapeutic intervention with a especially particular remedy against particular disorder [14]. Tocilizumab is an anti-IL6 receptor antibody, to treat with the Covid-19 [15]. The detection of SARS-CoV-2-specific IgM and IgG in patients furnished the groundwork for disorder diagnosis, in conjunction with RT-PCR-based tests. However, two studies, primarily based on the evaluation of 222 and 173 sufferers with COVID-19, respectively, suggested that sufferers with extreme ailment regularly had an extended IgG response and a greater titre of whole antibodies, which used to be related with worse consequence [16,17].

### Vaccines

Artificial Intelligence (AI) helps in growing vaccines and remedies at a whole lot of quicker price than typical and is additionally useful for scientific trials all through the improvement of the vaccine [18]. Vaccine improvement is a lengthy process, and no vaccines are on hand at the time of a pandemic outbreak. For example, the Ebola epidemic outbreak came about in 2013, and three years later, the rVSV Ebola Vaccine used to be chosen for segment I medical trials for its protection and immunogenicity in Africa and Europe [19]. In November 2019, the European Commission granted advertising authorization to Merck Sharp and Dohme B.V. in Europe for their Ebola vaccine, Ervebo. Fortunately, Moderna business enterprise introduced on February 24, 2020 that the company's experimental mRNA COVID-19 vaccine, recognised as mRNA-1273, is geared up for human testing. It is a remarkably speedy improvement cycle to improve an preliminary vaccine simply weeks after figuring out the SARS-CoV-2 genetic sequence. The medical trial of security and immunogenicity of mRNA-1273 in the remedy of COVID-19 is below investigation (ClinicalTrials.gov Identifier: NCT04283461). Moreover, a new oral SARS-CoV-2 vaccine has been efficiently developed at Tianjin University, which makes use of food-grade protected Sac-

charomyces cerevisiae as a service and objectives the S protein. There are 18 biotechnology corporations and universities in China working on SARS-CoV-2 vaccines. Vaccines for SARS-CoV-2 have been developed tons quicker than these for Ebola due to the fact of the collaborative efforts of scientists round the world and the fast-track approval of SARS-CoV-2 vaccine improvement efforts by using the Chinese fitness organizations [20,21]. Vaccines in opposition to the 2019-nCoV are in modern times in enhancement and none are in checking out (at the time of writing). The Coalition for Epidemic Preparedness Innovations delivered that they will fund vaccine enhancement programmes with Inovio, The University of Queensland and Moderna, Inc respectively, with the reason to take a seem to be at the experimental vaccines clinically in sixteen weeks (By June 2020). The vaccine candidates will be developed with the useful resource of the DNA, recombinant and mRNA vaccine buildings from these corporations [22]. Based on the most latest MERS-CoV outbreak, there are already a wide variety of vaccine candidates being developed however most are nonetheless in the preclinical checking out stage. The vaccines in improvement encompass viral vector-based vaccine, DNA vaccine, subunit vaccine, virus-like particles (VLPs)-based vaccine, inactivated whole-virus (IWV) vaccine and stay attenuated vaccine [23]. There used to be one SARS vaccine trial performed by using the US National Institute of Allergy and Infectious Diseases. Both Phase I scientific trials mentioned fine results, however solely one has announced plans to proceed to Phase 2 trial [24]. Vaccine Research Center of the National Institute of Allergy and Infectious Diseases, scientists are creating a vaccine candidate expressing SARS-CoV-2 S protein in the mRNA vaccine platform technology. This vaccine is predicted to bear scientific checking out in the coming months [25]. The opportunity of creating a usual CoV vaccine was once assessed primarily based on the similarity in T-cell epitopes of SARS- and MERS-CoV that tested the doable for cross-reactivity amongst CoVs [26].

### Antiviral agents

There is no contemporary proof from randomized managed trials (RCTs) to suggest any unique anti-SARS-CoV-2 therapy for sufferers with a suspected or proven COVID-19 infection. Lopinavir inhibits the protease pastime of coronavirus *in vitro* and in animal studies. A retrospective, matched-cohort find out about along with 1052 SARS sufferers confirmed that LPV/ritonavir as preliminary remedy used to be related with a decreased loss of life charge (2.3% vs. 11.0%) [27]. The protease inhibitor LPV is an positive remedy primarily based on the trip amassed from the SARS

and MERS outbreaks, indicating it is a attainable remedy choice for COVID-19 [28]. In addition, SARS-CoV-2 RNA-dependent RNA polymerase mannequin is centered via ribavirin after sequence analysis, modeling, and docking to construct the model. This function will increase its plausible as an antiviral towards SARS-CoV-2 [29]. Remdesivir was once used to deal with the first case of COVID-19 contamination in the United States: the patient's medical circumstance multiplied after solely one day of remdesivir therapy [30]. Several tablets such as chloroquine, arbidol, remdesivir, and favipiravir are presently present process scientific research to check their efficacy and security in the remedy of coronavirus sickness 2019 (COVID-19) in China; some promising effects have been performed for that reason far. This article summarizes sellers with achievable efficacy towards SARS-CoV-2 [31].

### Chloroquine and hydroxychloroquine

The first outcomes acquired from greater than a 100 sufferers confirmed the obvious efficacy of chloroquine in phrases of discount of exacerbation of pneumonia, length of signs and symptoms and prolong of viral clearance, all in the absence of extreme facet consequences. Chloroquine was once covered in the pointers for the prevention and cure of COVID-19 pneumonia [32,33]. 21 scientific research have been launched via Chinese hospitals and the University of Oxford to consider the efficacy of these retailers in COVID-19 contamination. It is additionally indispensable to decide whether or not the advantage of chloroquine remedy relies upon on the age of the affected person and the scientific presentation or stage of the disorder [34]. If scientific facts affirm the organic results, chloroquine and hydroxychloroquine may additionally be used in prophylaxis as nicely as healing therapy for folks reveal to SARS-CoV-2 [35]. Human trials of chloroquine confirmed no enhancement in chikungunya acute sickness and as a substitute an amplify in persistent arthralgia was once found at some point of post-illness period, in contrast to the controls [36]. The anti-viral and anti-inflammatory moves of chloroquine have led to severa trials urgently in the face of international fitness emergency. A Chinese find out about involving greater than one hundred sufferers of COVID-19 observed chloroquine optimum to the manipulate team in lowering symptom duration, exacerbation of pneumonia inclusive of radiological enhancement and advertising virus-negative seroconversion besides any extreme facet outcomes [37]. This is all genuine of chloroquine and hydroxychloroquine, both 4-aminoquinolines, which have been advised as potential treatments for covid-19. Currently, at least 8 trials of chloroquine, hydroxychloro-

quine, or both, now and again in combination with different drugs, are registered globally [38]. Hydroxychloroquine or chloroquine, frequently in mixture with a second-generation macrolide, are being extensively used for remedy of COVID-19 [39]. Chloroquine can inhibit the increase of extreme acute respiratory syndrome coronavirus have introduced this molecule into the spotlight. Hydroxychloroquine [HCQS], which is normally used in dermatology clinics for the administration of systemic lupus erythematosus and has a higher scientific protection profile and fewer drug-drug interactions than CQ, has additionally been verified to have anti-SARS-CoV recreation *in vitro* [40].

### Convalescent plasma transfusion

Current medical trials involving recovering plasma transfusion. The National Health Commission of China appealed to convalescent sufferers to donate blood for the remedy of COVID-19 infection. Convalescent plasma have to be gathered inside two weeks after restoration to make sure an excessive neutralization antibody titer. The issue in acquiring plasma throughout convalescence limits its scientific application. Well-designed scientific trials are wanted to similarly consider the efficacy and protection of convalescent plasma remedy in sufferers with COVID-19 infection [41]. In a laboratory test, the COVID-19 virus used to be removed from the bronchoalveolar lavage fluid of a seriously sick patient, and it ought to be neutralized by using sera from numerous sufferers [42]. In addition, the medical advantages of transfusing corresponding convalescent plasma had been additionally discovered in sufferers contaminated with Ebola virus, MERS-CoV, or influenza A H1N1. Convalescent plasma used to be bought from humans who had recovered from COVID-19 [43].

### Corticosteroids

In a learn about of forty one COVID-19 patients, 21% obtained corticosteroids, which ought to suppress lung irritation [44]. The administered dose of methylprednisolone diverse relying on disorder severity. Current meantime instruction from the WHO on the scientific administration of extreme acute respiratory contamination when SARS-CoV-2 contamination is suspected (released January 28, 2020) advises in opposition to the use of corticosteroids except indicated for any other reason. The scientific effects of coronavirus and comparable outbreaks do no longer help the use of corticosteroids. In a retrospective observational learn about of 309 adults who have been seriously sick with MERS, sufferers who had been given corticosteroids had been greater possibly to require

mechanical ventilation, vasopressors, and renal substitute remedy [45]. Corticosteroids have a correct inhibitory impact on inflammatory elements and are frequently used as an auxiliary cure for viral pneumonia. The foremost anti-inflammatory impact of glucocorticoids is to inhibit a massive range of pro-inflammatory genes that encode cytokines, chemokines, cell adhesion molecules, inflammatory enzymes, and receptors to tackle the inflammatory method and repair homeostasis. Corticosteroids have been extensively used in the course of outbreaks of extreme acute respiratory syndrome and Middle East respiratory syndrome, their efficacy remained highly controversial [46]. Corticosteroids are generally used to deal with extreme acute respiratory infections of viral aetiology due to the fact of their anti-inflammatory effect. However, it was once said that corticosteroids did no longer enhance consequences all through the SARS and MERS outbreaks, however delayed viral clearance and improved quotes of secondary infections [47]. Most different protected research investigated the use of corticosteroids alternatively than NSAIDs throughout the cure of coronaviruses. Various research in people mentioned that corticosteroids seemed tremendous in lowering immunopathological damage, however issues centred round the promoting of viral rebound and affiliation with detrimental activities (including acute respiratory misery syndrome) [48].

### Conclusion

The COVID-19 pandemic represents the best world public fitness disaster of this technology and, potentially, given that the pandemic influenza outbreak of 1918. The pace and extent of medical trials launched to inspect achievable healing procedures for COVID-19 spotlight each the want and functionality to produce incredible proof even in the center of a pandemic. No healing procedures have been proven advantageous to date.

### Bibliography

1. Liu Y, *et al.* "The reproductive number of COVID-19 is higher compared to SARS coronavirus". *Journal of Travel Medicine* (2020).
2. Tuite AR, *et al.* "Estimation of COVID-19 outbreak size in Italy". *The Lancet Infectious Diseases* 20.5 (2020): 537.
3. Torales J, *et al.* "The outbreak of COVID-19 coronavirus and its impact on global mental health". *International Journal of Social Psychiatry* (2020).



4. Wang D., et al. "Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China". *JAMA* 323.11 (2020): 1061-1069.
5. Chen N., et al. "Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study". *The Lancet* 395.10223 (2020): 507-513.
6. Huang C., et al. "Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China". *The Lancet* 395.10223 (2020): 497-506.
7. Singhal T. "A review of coronavirus disease-2019 (COVID-19)". *The Indian Journal of Pediatrics* (2020): 1-6.
8. Vardavas CI and Nikitara K. "COVID-19 and smoking: A systematic review of the evidence". *Tobacco Induced Diseases* 18 (2020).
9. Cortegiani A., et al. "A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19". *Journal of Critical Care* (2020).
10. Hoffmann M., et al. "SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor". *Cell* (2020).
11. Mulangu S., et al. "A randomized, controlled trial of Ebola virus disease therapeutics". *New England Journal of Medicine* 381.24 (2019): 2293-2303.
12. Mair-Jenkins J., et al. "The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: a systematic review and exploratory meta-analysis". *The Journal of infectious diseases* 211.1 (2015): 80-90.
13. Tian X., et al. "Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific human monoclonal antibody". *Emerging Microbes and Infections* 9.1 (2020): 382-385.
14. Shanmugaraj, B., et al. "Perspectives on monoclonal antibody therapy as potential therapeutic intervention for Coronavirus disease-19 (COVID-19)". *Asian Pacific Journal of Allergy and Immunology* 38.1 (2020): 10-18.
15. Michot JM., et al. "Tocilizumab, an anti-IL-6 receptor antibody, to treat COVID-19-related respiratory failure: a case report". *Annals of Oncology* (2020).
16. Zhang B., et al. "Immune phenotyping based on neutrophil-to-lymphocyte ratio and IgG predicts disease severity and outcome for patients with COVID-19". *medRxiv* (2020).
17. Zhao J., et al. "Antibody responses to SARS-CoV-2 in patients of novel coronavirus disease 2019". *Clinical Infectious Diseases* (2020).
18. Vaishya R., et al. "Artificial Intelligence (AI) applications for COVID-19 pandemic". *Diabetes and Metabolic Syndrome: Clinical Research and Reviews* (2020).
19. Agnandji ST., et al. "Phase 1 trials of rVSV Ebola vaccine in Africa and Europe". *New England Journal of Medicine* 374.17 (2016): 1647-1660.
20. Zhang N., et al. "Recent advances in the detection of respiratory virus infection in humans". *Journal of Medical Virology* 92.4 (2020): 408-417.
21. Mackenzie JS and Jeggo M. "Reservoirs and vectors of emerging viruses". *Current Opinion in Virology* 3.2 (2013): 170-179.
22. CEPI. Cepi to fund three programmes to develop vaccines against the novel coronavirus, ncov-2019.
23. Yong CY., et al. "Recent advances in the vaccine development against Middle East respiratory syndrome-coronavirus". *Frontiers in Microbiology* 10 (2019): 1781.
24. Inovio's Positive First-In-human Mers Vaccine Results Published in the Lancet Infectious Diseases; Athena Information Solutions Pvt. Ltd.: Mumbai, India (2019).
25. NIAID. Developing therapeutics and vaccines for coronaviruses (2020).
26. Liu WJ., et al. "T-cell immunity of SARS-CoV: Implications for vaccine development against MERS-CoV". *Antiviral Research* 137 (2017): 82-92.
27. Chan KS., et al. "Treatment of severe acute respiratory syndrome with lopinavir/ritonavir: a multicentre retrospective matched cohort study". *Hong Kong Medical Journal* (2003).

28. Yao TT, et al. "A systematic review of lopinavir therapy for SARS coronavirus and MERS coronavirus—A possible reference for coronavirus disease-19 treatment option". *Journal of Medical Virology* 92.6 (2020): 556-563.

29. Elfiky AA. "Anti-HCV, nucleotide inhibitors, repurposing against COVID-19". *Life Sciences* (2020): 117477.

30. Holshue ML, et al. "First case of 2019 novel coronavirus in the United States". *New England Journal of Medicine* (2020).

31. Dong L, et al. "Discovering drugs to treat coronavirus disease 2019 (COVID-19)". *Drug Discoveries and Therapeutics* 14.1 (2020): 58-60.

32. Gao J, et al. "Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies". *Bioscience Trends* (2020).

33. Jie Z, et al. "Expert consensus on chloroquine phosphate for the treatment of novel coronavirus pneumonia". *Zhonghua Jie He He Hu Xi Za Zhi* 43.3 (2020): 185-188.

34. Touret F and de Lamballerie X. "Of chloroquine and COVID-19". *Antiviral Research* (2020): 104762.

35. Colson P, et al. "Chloroquine for the 2019 novel coronavirus SARS-CoV-2". *International Journal of Antimicrobial Agents* 55.3 (2020): 105923.

36. Roques P, et al. "Paradoxical effect of chloroquine treatment in enhancing chikungunya virus infection". *Viruses* 10.5 (2018): 268.

37. Singh AK, et al. "Chloroquine and hydroxychloroquine in the treatment of COVID-19 with or without diabetes: A systematic search and a narrative review with a special reference to India and other developing countries". *Diabetes and Metabolic Syndrome: Clinical Research and Reviews* (2020).

38. Gothberg LA. "Severe infectious mononucleosis treated with chloroquine phosphate". *Journal of the American Medical Association* 173.1 (1960): 53-57.

39. Mehra MR, et al. "Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis". *The Lancet* (2020).

40. Jakhar D and Kaur I. "Potential of chloroquine and hydroxy-chloroquine to treat COVID-19 causes fears of shortages among people with systemic lupus erythematosus". *Nature Medicine* 26.5 (2020): 632-632.

41. Wrapp D, et al. "Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation". *Science* 367 (6483): 1260-1263.

42. Zhou P, et al. "A pneumonia outbreak associated with a new coronavirus of probable bat origin". *Nature* 579.7798 (2020): 270-273.

43. Zeng QL, et al. "Effect of convalescent plasma therapy on viral shedding and survival in patients with coronavirus disease 2019". *The Journal of Infectious Diseases* 222.1 (2020): 38-43.

44. Huang C, et al. "Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China". *The Lancet* 395.10223 (2020): 497-506.

45. Arabi YM, et al. "Corticosteroid therapy for critically ill patients with Middle East respiratory syndrome". *American Journal of Respiratory and Critical Care Medicine* 197.6 (2018): 757-767.

46. Yang Z, et al. "The effect of corticosteroid treatment on patients with coronavirus infection: a systematic review and meta-analysis". *Journal of Infection* (2020).

47. Zha L, et al. "Corticosteroid treatment of patients with coronavirus disease 2019 (COVID-19)". *Medical Journal of Australia* 212.9 (2020): 416-420.

48. Russell B, et al. "COVID-19 and treatment with NSAIDs and corticosteroids: should we be limiting their use in the clinical setting?". *E Cancer Medical Science* 14 (2020).

**Assets from publication with us**

- Prompt Acknowledgement after receiving the article
- Thorough Double blinded peer review
- Rapid Publication
- Issue of Publication Certificate
- High visibility of your Published work

**Website:** <https://www.actascientific.com/>

**Submit Article:** <https://www.actascientific.com/submission.php>

**Email us:** [editor@actascientific.com](mailto:editor@actascientific.com)

**Contact us:** +91 9182824667